348 related articles for article (PubMed ID: 28725583)
1. Positron emission tomography (PET) in primary prostate cancer staging and risk assessment.
Bednarova S; Lindenberg ML; Vinsensia M; Zuiani C; Choyke PL; Turkbey B
Transl Androl Urol; 2017 Jun; 6(3):413-423. PubMed ID: 28725583
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. Review of commonly used prostate specific PET tracers used in prostate cancer imaging in current clinical practice.
Niaz MJ; Sun M; Skafida M; Niaz MO; Ivanidze J; Osborne JR; O'Dwyer E
Clin Imaging; 2021 Nov; 79():278-288. PubMed ID: 34182326
[No Abstract] [Full Text] [Related]
4.
von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
[TBL] [Abstract][Full Text] [Related]
5. New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature.
Evangelista L; Briganti A; Fanti S; Joniau S; Reske S; Schiavina R; Stief C; Thalmann GN; Picchio M
Eur Urol; 2016 Jul; 70(1):161-175. PubMed ID: 26850970
[TBL] [Abstract][Full Text] [Related]
6. Positron emission tomography for prostate, bladder, and renal cancer.
Schöder H; Larson SM
Semin Nucl Med; 2004 Oct; 34(4):274-92. PubMed ID: 15493005
[TBL] [Abstract][Full Text] [Related]
7. The Performance of FDA-Approved PET Imaging Agents in the Detection of Prostate Cancer.
Li M; Zelchan R; Orlova A
Biomedicines; 2022 Oct; 10(10):. PubMed ID: 36289795
[TBL] [Abstract][Full Text] [Related]
8. New aspects of molecular imaging in prostate cancer.
Ceci F; Castellucci P; Cerci JJ; Fanti S
Methods; 2017 Nov; 130():36-41. PubMed ID: 28711565
[TBL] [Abstract][Full Text] [Related]
9. Molecular Imaging in Primary Staging of Prostate Cancer Patients: Current Aspects and Future Trends.
Manafi-Farid R; Ranjbar S; Jamshidi Araghi Z; Pilz J; Schweighofer-Zwink G; Pirich C; Beheshti M
Cancers (Basel); 2021 Oct; 13(21):. PubMed ID: 34771523
[TBL] [Abstract][Full Text] [Related]
10. A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol.
Hofman MS; Murphy DG; Williams SG; Nzenza T; Herschtal A; Lourenco RA; Bailey DL; Budd R; Hicks RJ; Francis RJ; Lawrentschuk N
BJU Int; 2018 Nov; 122(5):783-793. PubMed ID: 29726071
[TBL] [Abstract][Full Text] [Related]
11. Nuclear Medicine in Prostate Cancer: A New Era for Radiotracers.
Cuccurullo V; Di Stasio GD; Mansi L
World J Nucl Med; 2018; 17(2):70-78. PubMed ID: 29719480
[TBL] [Abstract][Full Text] [Related]
12. [
Bauman G; Martin P; Thiessen JD; Taylor R; Moussa M; Gaed M; Rachinsky I; Kassam Z; Chin J; Pautler S; Lee TY; Valliant JF; Ward A
Eur Urol Focus; 2018 Sep; 4(5):702-706. PubMed ID: 28753797
[TBL] [Abstract][Full Text] [Related]
13. Dual-Tracer Positron-Emission Tomography Using Prostate-Specific Membrane Antigen and Fluorodeoxyglucose for Staging of Prostate Cancer: A Systematic Review.
McGeorge S; Kwok M; Jiang A; Emmett L; Pattison DA; Thomas PA; Yaxley JW; Roberts MJ
Adv Urol; 2021; 2021():1544208. PubMed ID: 34456998
[TBL] [Abstract][Full Text] [Related]
14. A Systematic Review on the Role of Imaging in Early Recurrent Prostate Cancer.
De Visschere PJL; Standaert C; Fütterer JJ; Villeirs GM; Panebianco V; Walz J; Maurer T; Hadaschik BA; Lecouvet FE; Giannarini G; Fanti S
Eur Urol Oncol; 2019 Feb; 2(1):47-76. PubMed ID: 30929846
[TBL] [Abstract][Full Text] [Related]
15. Clinical implications of PET/CT in prostate cancer management.
Rayn KN; Elnabawi YA; Sheth N
Transl Androl Urol; 2018 Oct; 7(5):844-854. PubMed ID: 30456187
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic Role of
Awenat S; Piccardo A; Carvoeiras P; Signore G; Giovanella L; Prior JO; Treglia G
Diagnostics (Basel); 2021 Mar; 11(3):. PubMed ID: 33808825
[TBL] [Abstract][Full Text] [Related]
17. Rapidly changing landscape of PET/CT imaging in prostate cancer.
Morigi JJ; Fanti S; Murphy D; Hofman MS
Curr Opin Urol; 2016 Sep; 26(5):493-500. PubMed ID: 27467137
[TBL] [Abstract][Full Text] [Related]
18. ¹⁸F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer.
Rowe SP; Gage KL; Faraj SF; Macura KJ; Cornish TC; Gonzalez-Roibon N; Guner G; Munari E; Partin AW; Pavlovich CP; Han M; Carter HB; Bivalacqua TJ; Blackford A; Holt D; Dannals RF; Netto GJ; Lodge MA; Mease RC; Pomper MG; Cho SY
J Nucl Med; 2015 Jul; 56(7):1003-1010. PubMed ID: 26069305
[TBL] [Abstract][Full Text] [Related]
19. Diagnosis of recurrent prostate cancer with PET/CT imaging using the gastrin-releasing peptide receptor antagonist
Wieser G; Popp I; Christian Rischke H; Drendel V; Grosu AL; Bartholomä M; Weber WA; Mansi R; Wetterauer U; Schultze-Seemann W; Meyer PT; Jilg CA
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1463-1472. PubMed ID: 28417160
[TBL] [Abstract][Full Text] [Related]
20. Comparison Between
Cantiello F; Crocerossa F; Russo GI; Gangemi V; Ferro M; Vartolomei MD; Lucarelli G; Mirabelli M; Scafuro C; Ucciero G; De Cobelli O; Morgia G; Damiano R; Cascini GL
Clin Genitourin Cancer; 2018 Oct; 16(5):385-391. PubMed ID: 29937067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
